These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 23102539)
1. PET quantification of pancreatic VMAT 2 binding using (+) and (-) enantiomers of [¹⁸F]FP-DTBZ in baboons. Harris PE; Farwell MD; Ichise M Nucl Med Biol; 2013 Jan; 40(1):60-4. PubMed ID: 23102539 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of pancreatic VMAT2 binding with active and inactive enantiomers of Naganawa M; Lin SF; Lim K; Labaree D; Ropchan J; Harris P; Huang Y; Ichise M; Carson RE; Cline GW Nucl Med Biol; 2016 Dec; 43(12):743-751. PubMed ID: 27673755 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of Pancreatic VMAT2 Binding with Active and Inactive Enantiomers of [ Naganawa M; Lim K; Nabulsi NB; Lin SF; Labaree D; Ropchan J; Herold KC; Huang Y; Harris P; Ichise M; Cline GW; Carson RE Mol Imaging Biol; 2018 Oct; 20(5):835-845. PubMed ID: 29468404 [TBL] [Abstract][Full Text] [Related]
4. Deuterated Liu F; Choi SR; Zha Z; Ploessl K; Zhu L; Kung HF Nucl Med Biol; 2018 Feb; 57():42-49. PubMed ID: 29306111 [TBL] [Abstract][Full Text] [Related]
5. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters. Goswami R; Ponde DE; Kung MP; Hou C; Kilbourn MR; Kung HF Nucl Med Biol; 2006 Aug; 33(6):685-94. PubMed ID: 16934687 [TBL] [Abstract][Full Text] [Related]
6. Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters. Kung MP; Hou C; Goswami R; Ponde DE; Kilbourn MR; Kung HF Nucl Med Biol; 2007 Apr; 34(3):239-46. PubMed ID: 17383573 [TBL] [Abstract][Full Text] [Related]
7. In vivo imaging of beta-cell mass in rats using 18F-FP-(+)-DTBZ: a potential PET ligand for studying diabetes mellitus. Kung MP; Hou C; Lieberman BP; Oya S; Ponde DE; Blankemeyer E; Skovronsky D; Kilbourn MR; Kung HF J Nucl Med; 2008 Jul; 49(7):1171-6. PubMed ID: 18552132 [TBL] [Abstract][Full Text] [Related]
8. Cross-sectional and Test-Retest Characterization of PET with [(18)F]FP-(+)-DTBZ for β Cell Mass Estimates in Diabetes. Freeby MJ; Kringas P; Goland RS; Leibel RL; Maffei A; Divgi C; Ichise M; Harris PE Mol Imaging Biol; 2016 Apr; 18(2):292-301. PubMed ID: 26370678 [TBL] [Abstract][Full Text] [Related]
9. PET Imaging of Vesicular Monoamine Transporter 2 in Early Diabetic Retinopathy Using [ Li J; Chen P; Bao Y; Sun Y; He J; Liu X Mol Imaging Biol; 2020 Oct; 22(5):1161-1169. PubMed ID: 31650482 [TBL] [Abstract][Full Text] [Related]
10. Effects of anesthetics on vesicular monoamine transporter type 2 binding to ¹⁸F-FP-(+)-DTBZ: a biodistribution study in rat brain. Chen Z; Tang J; Liu C; Li X; Huang H; Xu X; Yu H Nucl Med Biol; 2016 Jan; 43(1):124-129. PubMed ID: 26526872 [TBL] [Abstract][Full Text] [Related]
11. An Efficient Automated Radiosynthesis and Bioactivity Confirmation of VMAT2 Tracer [ Zhao C; Liu C; Tang J; Xu Y; Xie M; Chen Z Mol Imaging Biol; 2020 Apr; 22(2):265-273. PubMed ID: 31165386 [TBL] [Abstract][Full Text] [Related]
12. In vivo imaging of vesicular monoamine transporter 2 in pancreas using an (18)F epoxide derivative of tetrabenazine. Kung HF; Lieberman BP; Zhuang ZP; Oya S; Kung MP; Choi SR; Poessl K; Blankemeyer E; Hou C; Skovronsky D; Kilbourn M Nucl Med Biol; 2008 Nov; 35(8):825-37. PubMed ID: 19026944 [TBL] [Abstract][Full Text] [Related]
13. Sigma receptor binding of tetrabenazine series tracers targeting VMAT2 in rat pancreas. Tsao HH; Skovronsky DM; Lin KJ; Yen TC; Wey SP; Kung MP Nucl Med Biol; 2011 Oct; 38(7):1029-34. PubMed ID: 21982574 [TBL] [Abstract][Full Text] [Related]
14. Study of Vesicular Monoamine Transporter 2 in Myopic Retina Using [ Sun Y; Zhao N; Liu W; Liu M; Ju Z; Li J; Cheng Z; Liu X Mol Imaging Biol; 2018 Oct; 20(5):771-779. PubMed ID: 29520623 [TBL] [Abstract][Full Text] [Related]
15. 11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls. Goland R; Freeby M; Parsey R; Saisho Y; Kumar D; Simpson N; Hirsch J; Prince M; Maffei A; Mann JJ; Butler PC; Van Heertum R; Leibel RL; Ichise M; Harris PE J Nucl Med; 2009 Mar; 50(3):382-9. PubMed ID: 19223416 [TBL] [Abstract][Full Text] [Related]
16. Assessment of islet specificity of dihydrotetrabenazine radiotracer binding in rat pancreas and human pancreas. Fagerholm V; Mikkola KK; Ishizu T; Arponen E; Kauhanen S; Någren K; Solin O; Nuutila P; Haaparanta M J Nucl Med; 2010 Sep; 51(9):1439-46. PubMed ID: 20720057 [TBL] [Abstract][Full Text] [Related]
17. Binding characteristics of 9-fluoropropyl-(+)-dihydrotetrabenzazine (AV-133) to the vesicular monoamine transporter type 2 in rats. Tsao HH; Lin KJ; Juang JH; Skovronsky DM; Yen TC; Wey SP; Kung MP Nucl Med Biol; 2010 May; 37(4):413-9. PubMed ID: 20447551 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of [(18)F]fluoroalkyl derivatives of dihydrotetrabenazine in rat and monkey brain. Kilbourn MR; Hockley B; Lee L; Hou C; Goswami R; Ponde DE; Kung MP; Kung HF Nucl Med Biol; 2007 Apr; 34(3):233-7. PubMed ID: 17383572 [TBL] [Abstract][Full Text] [Related]
19. MicroPET imaging of vesicular monoamine transporter 2 revealed the potentiation of (+)-dihydrotetrabenazine on MPTP-induced degeneration of dopaminergic neurons. Xu Y; Tang J; Liu C; Zhao C; Cao S; Yu H; Chen Z; Xie M Nucl Med Biol; 2021; 96-97():9-18. PubMed ID: 33647803 [TBL] [Abstract][Full Text] [Related]
20. Imaging of VMAT2 binding sites in the brain by (18)F-AV-133: the effect of a pseudo-carrier. Zhu L; Qiao H; Lieberman BP; Wu J; Liu Y; Pan Z; Ploessl K; Choi SR; Chan P; Kung HF Nucl Med Biol; 2012 Oct; 39(7):897-904. PubMed ID: 22749185 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]